| Literature DB >> 35494167 |
Nuran Katgi1, Pinar Çimen1, Ali Kadri Çirak1, Tarik Şimşek1, Kenan Can Ceylan2, Özgür Samancilar2, Elif Duman2, Onur Fevzi Erer1, Fatma Fevziye Tuksavul1.
Abstract
Aim and introduction: Diagnosing of interstitial lung disease (ILD) is difficult and expensive. The standard diagnostical approaches to ILD are bronchoalveolar lavage, transbronchial lung biopsy, transbronchial lung cryobiopsy (TBLC) and surgical lung biopsy (SLB). SLB is gold standard for the confident diagnosis of ILD but because of the poor performance of the patients it's use is limited. We conducted a retrospective study to point out that TBLC plays an important role in diagnosis of ILD and has fewer complications and lower cost than awake video-assisted thoracic surgery (AVATS). Material and methods: 132 patients who underwent TBLC and AVATS with a pre-diagnosis of ILD in our hospital between 2015 and 2020 were evaluated retrospectively. Diagnosis rates, complications and costs were recorded.Entities:
Keywords: Interstitial lung disease; awake video-assisted thoracic surgery; complication; cost; transbronchial lung cryobiopsy
Year: 2022 PMID: 35494167 PMCID: PMC9007030 DOI: 10.36141/svdld.v39i1.12293
Source DB: PubMed Journal: Sarcoidosis Vasc Diffuse Lung Dis ISSN: 1124-0490 Impact factor: 0.670
Demographic datas and clinical characteristics of patients
| TBLC n=88 | VATS n=44 | |
|---|---|---|
| Age(mean±sd) | 58.1±9.6 | 56.3±12.6 |
| Female | 41 (46.6%) | 24 (54.5%) |
| Male | 47 (53.4%) | 20 (45.5%) |
| Smoking status n (%) | ||
| Smoker | 21 (23.9%) | 8 (18.2%) |
| Ex-smoker | 25 (28.4%) | 11 (25.0%) |
| Never smoker | 42 (47.7%) | 25 (56.8%) |
| Additional illness | ||
| COPD | 18 (20.4%) | 0 (0.0%) |
| HT | 61 (69.3%) | 8 (18.1%) |
| CHF | 29(32.9%) | 5 (11.3%) |
| DM | 19 (%21.5) | 3 (6.8%) |
| Symptom n (%) | 85 (96.6%) | 44 (100.9%) |
| Cough | 52 (59.1%) | 31 (40.9%) |
| Dyspnea | 68 (77.3%) | 38 (86.4%) |
| Sputum | 11 (12.5%) | 7 (15.9%) |
| Number of areas biopsied n (%) | ||
| One area | 87 (98.8%) | 16 (35.4%) |
| Multiple areas | 1 (1.1%) | 28 (63.6%) |
| Diagnosis n (%) | ||
| Chronic nonspecific inflamation | 14 (15.9%) | 0 (0.0%) |
| Non-diagnostic | 10 (11.3%) | 0 (0.0%) |
| UIP | 21 (23.9%) | 28 (63.6%) |
| HSP | 9 (10.2%) | 6 (13.6%) |
| OP | 10 (11.4%) | 3 (6.8%) |
| Lung cancer | 4 (4.5%) | 0 (0.0%) |
| NSIP | 6 (6.8%) | 2 (4.5%) |
| Follicular Bronchiolitis | 1 (1.1%) | 1 (2.3%) |
| Unclassified ILD | 2 (2.3%) | 0 (0.0%) |
| Alveolar proteinosis | 1 (1.1%) | 2 (4.5%) |
| Sarkoidoz | 1 (1.1%) | 0 (0.0%) |
| Eosinophilic pneumonia | 4 (4.5%) | 1 (2.3%) |
| Metastatic lung carcinoma | 2 (2.3%) | 0 (0.0%) |
| Pneumoconiosis | 1 (1.1%) | 1 (2.3%) |
| Granulomatosis infection | 1 (1.1%) | 0 (0.0%) |
| DAH | 1 (1.1%) | 0 (0.0%) |
| Chest tube requirement n (%) | 1 (1.1%) | 44 (100.0%) |
| Duration of chest tube (days) (median) min-max) | 0.0 (0-6) | 4.0 (2-28) |
COPD: Chronic obstructive pulmonary disease, HT: Hypertension, CHF: Congestive heart failure, DM: Diabetes mellitus, UIP: Usual interstitial pneumonia, OP: Organizing pneumonia, NSIP: Nonspecific interstitial pneumonia, ILD: Interstitial lung disease, DAH: Diffuse alveolar hemorrhage.
Complications and costanalysis
| TBLC n=88 | VATS n=44 | p value | |
|---|---|---|---|
| Complications n (%) | 48 (54.5%) | NA | NA |
| Hemorrhage n (%) | |||
| Mild | 26 (61.9%) | NA NA NA NA | |
| Moderate | 15 (35.7%) | NA | |
| Massive | 1 (2.4%) | NA | NA |
| None | 46 (52.3%) | NA | |
| Pneumothorax | 6 (6.8%) | NA | NA |
| PAL | 1 (1,1%) | 11 (25.0%) | <0.001 |
| HV | 0 (0.0%) | 6 (13.6%) | 0.001 |
| Duration of hospitalisation (days) (median) (min-max) | 2.0 (1.0-21.0) | 8 (3.0-46.0) | <0.001 |
| Cost (Dolar) (median) (min-max) | 171.9 (80.8-1493.3) | 515.9 (415.2-2662.9) | <0.001 |
PAL: Prolonged air leak, HV: Heimlich valve, NA: Not available